AbbVie (NYSE:ABBV) has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its most recent quarter. AbbVie's reliance on Humira has brought criticism from some stock observers, although the drug has patent protection until 2016-and even then, generic drugmakers have been hard-pressed to develop copies of biologic drugs such as Humira in the past, so expect AbbVie's top therapy to continue producing top-notch revenue for some time.

However, savvy investors keep an eye on the long term -- and AbbVie's doing the same. The company's gearing up for the future with a pipeline sporting several promising drugs. AbbVie's oral hepatitis C compound has garnered the most attention as the company's entrant into the race to secure a slice of what could amount to a $20 billion market, but it has more potential blockbusters under development that could deliver for investors in the future.

Which drugs are the best bets in the long run for investors? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through three drugs with the potential to lead AbbVie's long-term plans and deliver for investors for years to come.

Top dividend stocks for the next decade -- better than AbbVie?
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers